• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Cooperation cuts FDA approval times

Article

Kissimmee, Fla. — The time it takes for the U.S. Food and Drug Administration (FDA) approval of a new dermatology drug or treatment depends on many factors, including how closely pharmaceutical companies cooperate with the agency.

Related Videos
Related Content
Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

Patients With Hidradenitis Suppurativa Have Increased Odds of Respiratory Disease, According to Study Findings

Article
The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

The Cutaneous Connection: Make Data-Driven Decisions For Personalized AD Treatment

Podcast
Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Federal Trade Commission Votes to Ban Noncompete Clauses Between Employers and Workers

Article
ReV Up Your Vitiligo Treatment Strategies

ReV Up Your Vitiligo Treatment Strategies

Podcast
US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

US Central and European Commands Should Revisit Disallowance of Systemic Treatments for Deployed Individuals With Psoriasis, Eczema, Paper Argues

Article
Ruxolitinib, Educational Initiatives for Managed Care Professionals Play Crucial Role in Optimizing Care in Atopic Dermatitis

Ruxolitinib, Educational Initiatives for Managed Care Professionals Play Crucial Role in Optimizing Care in Atopic Dermatitis

Article
© 2024 MJH Life Sciences

All rights reserved.